28 January 2020
FDA published final guidance on Jan. 23, 2020 that provides information regarding FDA’s implementation of the Biosimilar User Fee Amendments of 2017 (BsUFA II) under Title IV of the FDA Reauthorization Act of 2017. The guidance details the new fee structure and types of fees created as a result of BsUFA II.
Specifically, the guidance explains the process for submitting payments, the consequences for not paying BsUFA fees, and how to request reconsideration of a user fee assessment. FDA also describes how it determines which products are subject to fees. It does not, however, address how the agency determines and adjusts fees each fiscal year or how it addresses implementation of other user fee programs.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024